Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients

摘要

Objective: Our aim was to determinate the acenocoumarol dose requirement in highly sensitive geriatric patients, based on a minimum of genotype (VKORC1 and CYP2C9) data. Methods: We used a Gaussian kernel density estimation test to identify patients highly sensitive to the drug and PHARMACHIP (R) -Cuma test (Progenika Biopharma, SA, Grifols, Spain) to determine the CYP2C9 and VKORCI genotype. Results: All highly sensitive geriatric patients were taking <= 5.6 mg/week of acenocoumarol (AC), and 86% of these patients presented the following genotypes: CYP2C9*1/*3 or CYP2C9*1/*2 plus VKORC1 A/G, CYP2C9*3/*3, or VKORCI A/A. Conclusion: VKORCI A and CYP2C9 *2 and/or *3 allelic variants extremely influence on AC dose requirement of highly sensitive geriatric patients. These patients display acenocoumarol dose requirement of <= 5.6 mg/week.